18 August 2022
18 August 2022
24 August 2022
One of the hallmarks of multiple myeloma (MM), a cancer of the bone marrow and one of the most frequent haematological cancers worldwide, is the disruption of the patients’ immune system, which allows the cancer to progress. Now, a study performed by Cristina João, who leads the Myeloma and Lymphoma Research Group at the Champalimaud Centre for the Unknown, and her colleagues, shows how so-called extracellular vesicles (EV’s) released by multiple myeloma cells can drive the disruption of the immune system.
The overall goal of this event is to highlight examples from international funding entities that are either already piloting or considering implementing different models to allocate research funds, with a particular emphasis on the partial randomisation process, and highlight the perspective of researchers on this topic.
The session will end with a roundtable discussion featuring the views from researchers hosted by Portuguese institutions on whether partial randomisation is an appropriate alternative to the current peer review process.
28 July 2022